CTIS2023-507448-36-00招募中1 期
A Phase III randomised, double-blind, multicentre study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB27 (proposed pembrolizumab biosimilar) and Keytruda in subjects with metastatic non-squamous non-small cell lung cancer - SB27-3004
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 616
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Male or female = 18 years of age, Have been diagnosed with stage IV non-squamous NSCLC, Have not received any prior systemic anti-cancer therapy for metastatic NSCLC, Agree to use adequate methods of contraception
排除标准
- •Unable to take folic acid and vitamin B12 supplementation, Unable to receive chemotherapy during the study
研究者
相似试验
已完成
不适用
A Phase III randomised, double-blind, multicentre study to evaluate the safety and efficacy of 1592U89 (abacavir) in human immunodeficiency virus 1-infected patients with aquired immune deficiency syndrome dementia complexHIV-1 infection with AIDS dementiaInfections and InfestationsHIV, AIDSISRCTN53707238GlaxoSmithKline (UK)90
尚未招募
3 期
Study which tests 2 medications (SB27, Keytruda) to compare how effective, safe and well tolerated in a large number of metastatic non-squamous non-small cell lung cancer patients.CTRI/2024/02/062974Samsung Bioepis Co Ltd
进行中（未招募）
1 期
A study to evaluate the efficacy, safety, and tolerability of dolutegravir pluslamivudine compared to dolutegravir plus tenofovir/emtricitabine in HIV-1-infected patients that have not been treated yet.Human Immunodeficiency Virus-1 infectionMedDRA version: 20.1Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862EUCTR2016-000459-28-PTViiV Healthcare UK Limited700
进行中（未招募）
1 期
A study to evaluate the efficacy, safety, and tolerability of dolutegravir plus lamivudine compared to dolutegravir plus tenofovir/emtricitabine in HIV-1-infected patients that have not been treated yet.Human Immunodeficiency Virus-1 infectionMedDRA version: 19.0Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862EUCTR2015-004418-95-ESViiV Healthcare UK Limited719
进行中（未招募）
1 期
A study to evaluate the efficacy, safety, and tolerability of dolutegravir plus lamivudine compared to dolutegravir plus tenofovir/emtricitabine in HIV-1-infected patients that have not been treated yet.EUCTR2015-004418-95-BEViiV Healthcare UK Limited719